Loading clinical trials...
Loading clinical trials...
Identification Des Bases moléculaires de l'éjaculation prématurée Primaire
The main objective of our study is to identify the first genetic etiology of primary Premature Ejaculation (PE). We will test and evaluate the existence of genetic determinism conferring susceptibility to a life-long syndrome (primary premature ejaculation) in some patients. To this end, we plan to establish a collection of biological samples and a database of patients with this extreme syndrome, which we will analyze by Genome Wide analysis. This will lead to improvements in the biological understanding, the "knowledge" of physicians of the disease, and should improve the patients' quality of life. Not all PE cases have the same physiopathology and treatment efficiency, which depend on the specific mechanism involved in the clinical context. Our work will make it possible to develop new therapeutic approaches suitable for a large proportion of individuals presenting PE. This integrative approach combining researchers, patients and ethics committees will facilitate profound reflection, promoting the creation of suitable structures capable of receiving patients for appropriate consultations. This unique study of PE should also favor industrial partnerships.
2.1 Main Objective * To identify the molecular basis of primary premature ejaculation (PPE) in humans for the development of new adapted therapy. * Check and confirm the genetic hypothesis of PPE to fill the void of genetic knowledge about this syndrome. * Improve knowledge of physicians on this disease to increase the comfort of life of patients. 2.2 Secondary Objectives * Provide the basis for new therapeutic approaches. * Expanded knowledge of the aetiology of PE and allow better management of patients. * Develop strategies to prevent the consequences, sometimes severe , of this condition on the intimate, personal, social and professional life of these patients. Because all the PE do not have the same pathophysiology and treatment success depends on its relevance to the specific mechanism of the clinical form concerned. * Increase the comfort of life of the patients. * Eliminate public prejudice based on misconceptions.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
Yes
Polyclinique de Blois
La Chaussée-Saint-Victor, France
Hôpital Saint Joseph
Marseille, France
Hôpital Necker
Paris, France
Start Date
April 1, 2014
Primary Completion Date
February 11, 2020
Completion Date
February 11, 2020
Last Updated
March 14, 2025
70
ACTUAL participants
Blood sample
PROCEDURE
Skin biopsy
PROCEDURE
Questionnaire
OTHER
Lead Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
NCT07434271
NCT06570135
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07236632